RxDoctor Payments Data

Bruce Goldstick, MD

Ophthalmology · Skokie, ILNPI 1215037247

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 43 payments — averaging $30.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$767
  • Novartis$111
  • Bausch & Lomb Americas Inc.$105
  • AbbVie$102
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$68
  • Aerie Pharmaceuticals, Inc.$44
  • plus $129 from 5 others

What the payments were for

  • Travel & lodging$121%
  • Food & beverage$1,31499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 50th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$479,856
Medicare patients
1,787
Services billed
4,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$55,817
LumiganBimatoprost75$35,443
VyzultaLatanoprostene Bunod39$17,850
Latanoprost1,078$12,144
RocklatanNetarsudil Mesylat/Latanoprost26$10,066
Prednisolone Acetate172$8,002
Cyclosporine23$7,437
Tobramycin-DexamethasoneTobramycin/Dexamethasone166$6,715
Fluorometholone76$5,668
BetimolTimolol20$4,455
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,993
Travoprost13$3,753
Timolol Maleate308$2,776
SimbrinzaBrinzolamide/Brimonidine Tart12$2,667
Levobunolol Hcl93$2,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$102$91,260147 claims
Bausch & Lomb Americas Inc.Vyzulta$105$17,85039 claims
Aerie Pharmaceuticals, Inc.Rocklatan$44$10,06626 claims
AlconSimbrinza$767$2,66712 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$68$1,54615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →